论文部分内容阅读
目的探讨凯西莱预防抗肿瘤药物致肝损害的临床疗效。方法将2004年3月-2008年8月入住我院的肿瘤病人116例随机分为凯西莱(硫普罗宁)治疗组65例,单纯化疗对照组51例。观察两组患者血清ALT、AST、TBIL情况及肝损害发生率。结果治疗组血清ALT、AST、TB较对照组明显降低,差异均有统计学意义(P<0.05);治疗组和对照组化疗后肝功能指标均明显低于化疗前,差异有统计学意义(P<0.05)。治疗组仅6例患者出现肝损害(9.23%),明显低于对照组肝损害发生率(16/51,31.4%)。结论在化疗期间使用抗肿瘤药物的同时加用凯西莱,能预防抗肿瘤药物致肝损害,值得临床进一步推广使用。
Objective To explore the clinical efficacy of Cassireil in preventing liver damage caused by antineoplastic agents. Methods One hundred and sixty-six patients with cancer who were admitted to our hospital from March 2004 to August 2008 were randomly divided into two groups: 65 cases treated with Cassirattin (tiopronin) and 51 cases treated with chemotherapy alone. The serum levels of ALT, AST, TBIL and the incidence of liver damage in both groups were observed. Results The levels of serum ALT, AST and TB in the treatment group were significantly lower than those in the control group (P <0.05). The indexes of liver function in the treatment group and the control group after chemotherapy were significantly lower than those before chemotherapy (P <0.05) P <0.05). Only 6 patients in the treatment group had liver damage (9.23%), which was significantly lower than that in the control group (16/51, 31.4%). Conclusion The use of anti-cancer drugs during chemotherapy with Kexilei, can prevent anti-tumor drug-induced liver damage, it is worth further promotion of clinical use.